(Q34982598)

5 August 2017

1 reference

title

Rationale and options for the long-term treatment of depression (English)

1 reference

5 August 2017

Martin B Keller

1 reference

5 August 2017

publication date

1 June 2002

1 reference

5 August 2017

published in

Human Psychopharmacology

1 reference

5 August 2017

volume

17 Suppl 1

1 reference

5 August 2017

page(s)

S43-6

1 reference

Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects

5 August 2017

cites work

1 reference

Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey

21 January 2018

1 reference

Recovery after 5 years of unremitting major depressive disorder.

21 January 2018

1 reference

Mirtazapine compared with paroxetine in major depression

21 January 2018

1 reference

7 January 2021

Sertraline in the prevention of depression

1 reference

7 January 2021

The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression

1 reference

7 January 2021

Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression

1 reference

7 January 2021

Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.

1 reference

7 January 2021

Paroxetine is better than placebo in relapse prevention and the prophylaxis of recurrent depression

1 reference

7 January 2021

A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression.

1 reference

7 January 2021

Mirtazapine versus amitriptyline in the long-term treatment of depression: a double-blind placebo-controlled study

1 reference

7 January 2021

Evidence-Based Health Policy---Lessons from the Global Burden of Disease Study

1 reference

7 January 2021

Efficacy of mirtazapine for prevention of depressive relapse: a placebo-controlled double-blind trial of recently remitted high-risk patients.

1 reference

7 January 2021

The functioning and well-being of depressed patients. Results from the Medical Outcomes Study

1 reference

7 January 2021

Identifiers

DOI

10.1002/HUP.400

1 reference

5 August 2017

1 reference